Histone deacetylation meets miRNA: Epigenetics and post-transcriptional regulation in cancer and chronic diseases

Expert Opinion on Biological Therapy

Volumn 15, Issue 5, 2015, Pages 651-664

  Swierczynski, Stefan ^a   Klieser, Eckhard ^a   Illig, Romana ^a   Alinger Scharinger, Beate ^a   Kiesslich, Tobias ^a   Neureiter, Daniel ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Epigenetics; Histone deacetylase; MicroRNA

Indexed keywords

ABEXINOSTAT; BELINOSTAT; ENTINOSTAT; FIBROBLAST GROWTH FACTOR 2; FUCOSYLTRANSFERASE; GIVINOSTAT; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; MICRORNA; MOCETINOSTAT; PANOBINOSTAT; POLYCYSTIN 2; QUISINOSTAT; RESMINOSTAT; ROMIDEPSIN; SIRTUIN; VALPROIC ACID; VORINOSTAT;

CARCINOGENESIS; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DEACETYLATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HISTONE ACETYLATION; HUMAN; NEOPLASM; NONHUMAN; REVIEW; TRANSCRIPTION REGULATION; BIOSYNTHESIS; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING; RNA PROCESSING;

CHRONIC DISEASE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; MICRORNAS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84927625304     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1025047     Document Type: Review

References (92)

1. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1(1): 19-25
2. Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol 2013; 1(1): 3-11
3. Stasevich TJ, Hayashi-Takanaka Y, Sato Y, et al. Regulation of RNA polymerase II activation by histone acetylation in single living cells. Nature 2014; 516(7530): 272-5
4. Sawa H, Murakami H, Ohshima Y, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol 2001; 18: 109-14
5. Wilting RH, Yanover E, Heideman MR, et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010; 29: 2586-97
6. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998; 391: 597-601
7. Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 2000; 97: 13708-13
8. Medina V, Edmonds B, Young GP, et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997; 57: 3697-707
9. Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci 2014; 10(7): 757-70
10. Stintzing S, Kemmerling R, Kiesslich T, et al. Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?. J Biomed Biotechnol 2011; 2011: 214143
11. Lujambio A, Calin GA, Villanueva A, et al. DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105(36): 13556-61
12. Ropero S, Fraga MF, Ballestar E, et al a truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006; 38(5): 566-9
13. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett 2009; 277(1): 8-21
14. Millard CJ, Watson PJ, Celardo I, et al. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell 2013;51(1):57-67
15. Kaluza D, Kroll J, Gesierich S, et al. Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells arterioscler Thromb Vasc Biol 2013; 33(3): 533-43
16. Morris MJ, Monteggia LM. Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. Int J Dev Neurosci 2013; 31(6): 370-81
17. Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013; 6: 1399-416
18. De Oliveira MV, Andrade JM, Parai'so AF, Santos SH. Sirtuins and cancer: new insights and cell signaling. Cancer Invest 2013; 31(10): 645-53
19. Deubzer HE, Schier MC, Oehme I, et al. HDAC11 is a novel drug target in carcinomas. Int J Cancer 2013; 132(9): 2200-8
20. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012; 6(6): 579-89
21. Wendtner CM. Cocktail of eternity: HDAC meets miR. Blood 2012; 119(5): 1095-6
22. Chatterjee N, Wang WL, Conklin T, et al. Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol Ther 2013; 14(7): 658-71
23. Noonan EJ, Place RF, Pookot D, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer Function of miR-449a in prostate cancer. Oncogene 2009; 28: 1714-24
24. Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/ WAF1.). Mol Ther 2013; 21(9): 1678-86
25. Nalls D, Tang SN, Rodova M, et al. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 2011; 6(8): e24099
26. Lodrini M, Oehme I, Schroeder C, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res 2013; 41(12): 6018-33
27. Chen CQ, Chen CS, Chen JJ, et al. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Mol Cell Biochem 2013; 383(1-2): 137-48
28. Wang Y, Toh HC, Chow P, et al. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012; 26(7): 3032-41
29. Sandhu SK, Volinia S, Costinean S, et al. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci USA 2012; 109(49): 20047-52
30. Winbanks CE, Wang B, Beyer C, et al. TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 2011; 286(16): 13805-14
31. Winbanks CE, Beyer C, Hagg A, et al. miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLoS One 2013; 8(9): e73589
32. Wang Z, Qin G, Zhao TC. HDAC4: mechanism of regulation and biological functions. Epigenomics 2014; 6(1): 139-50
33. Li H, Xie H, Liu W, et al a novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 2009; 119(12): 3666-77
34. Simon D, Laloo B, Barillot M, et al a mutation in the 3'-UTR of the HDAC6 gene abolishing the posttranscriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum Mol Genet 2010; 19(10): 2015-27
35. Huang S, Wang S, Bian C, et al. Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem Cells Dev. 2012; 21(13): 2531-40
36. Lwin T, Zhao X, Cheng F, et al a microenvironment-mediated c-Myc/ miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013; 123(11): 4612-26
37. Kai Y, Peng W, Ling W, et al. Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. Biochem Biophys Res Commun 2014; 448(3): 308-14
38. Yu XF, Zou J, Bao ZJ, Dong J. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol 2011; 17(42): 4711-17
39. Sekiya T, Adachi S, Kohu K, et al. Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factorbeta signaling, as a target of the betacatenin pathway in colorectal tumor cells. J Biol Chem 2004; 279(8): 6840-6
40. Elyada E, Pribluda A, Goldstein RE, et al. CKIa ablation highlights a critical role for p53 in invasiveness control. Nature 2011; 470(7334): 409-13
41. Konsavage WM Jr, Yochum GS. The myc 3' wnt-responsive element suppresses colonic tumorigenesis. Mol Cell Biol 2014; 34(9): 1659-69
42. Piard F, Martin L, Chapusot C, et al. [Genetic pathways in colorectal cancer: interest for the pathologist] ann Pathol 2002; 22(4): 277-88
43. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006; 20(5): 586-600
44. Kaluza D, Kroll J, Gesierich S, et al. Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells arterioscler Thromb Vasc Biol 2013; 33(3): 533-43
45. Lin L, Hou J, Ma F, et al. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J Immunol 2013; 191(7): 3896-904
46. Shi B, Xu W. The development and potential clinical utility of biomarkers for. HDAC inhibitors. Drug Discov Ther 2013; 7(4): 129-36
47. New M. Olzscha H, La Thangue NB. HDAC. inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6(6):637-56
48. Saccone V, Consalvi S, Giordani L, et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-Adipogenic progenitors in dystrophic muscles. Genes Dev 2014; 28(8): 841-57
49. Cheng TL, Wang Z, Liao Q, et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/ Drosha complex. Dev Cell 2014; 28(5): 547-60
50. Pushpavalli SN, Ramaiah MJ, Lavanya A, et al. Imidazo-benzothiazoles a potent microRNA modulator involved in cell proliferation. Bioorg Med Chem Lett 2012; 22(20): 6418-24
51. Hughes DP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 2009; 152: 479-96
52. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012; 4(1): 5
53. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013; 7: 47-60
54. Muinelo-Romay L, Villar-Portela S, Cuevas Alvarez E, et al a(1, 6) Fucosyltransferase expression is an independent prognostic factor for diseasefree survival in colorectal carcinoma. Hum Pathol 2011; 42(11): 1740-50
55. Bernardi C, Soffientini U, Piacente F, Tonetti MG. Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS One 2013; 8(10): e76540
56. Mizuno S, Yasuo M, Bogaard HJ, et al. Inhibition of histone deacetylase causes emphysema am J Physiol Lung Cell Mol Physiol 2011; 300(3): L402-13
57. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009; 4(8): e6816
58. Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/ WAF1.). Mol Ther 2013; 21(9): 1678-86
59. Zhang HS, Chen XY, Wu TC, et al. MiR-34a is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation through the SIRT1/NFjB pathway. FEBS Lett 2012; 586(23): 4203-7
60. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013; 20(12): 1603-14
61. Luo T, Cui S, Bian C, Yu X. Crosstalk between TGF-b/Smad3 and BMP/ BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. Mol Cell Biochem 2014; 389(1-2): 169-76
62. Sato Y. Is histone deacetylase-9-MicroRNA-17~92 cluster a novel axis for angiogenesis regulation? arterioscler Thromb Vasc Biol 2013; 33(3): 445-6
63. Patel V, Williams D, Hajarnis S, et al. miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci USA 2013; 110(26): 10765-70
64. Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011; 30(41): 4231-42
65. Cheng L, Luo S, Jin C, et al. FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 2013; 4: e923
66. Bernardi C, Soffientini U, Piacente F, Tonetti MG. Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS ONE 2013; 8(10): e76540
67. Wang M, Wang J, Kong X, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep 2014; 4: 6145
68. Gargalionis AN, Korkolopoulou P, Farmaki E, et al. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. Int J Cancer 2015; 136(7): 1515-27
69. Patel V, Williams D, Hajarnis S, et al. miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci USA 2013; 110(26): 10765-70
70. Li X. Epigenetics and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 2011; 1812(10): 1213-18
71. Masola V, Gambaro G, Tibaldi E, et al. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 2012; 287(2): 1478-88
72. Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011; 30(41): 4231-42
73. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74
74. Borbone E, De Rosa M, Siciliano D, et al. Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells. J Clin Endocrinol Metab 2013; 98(6): E1031-40
75. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012; 4(4): 505-24
76. Shi B, Xu W. The development and potential clinical utility of biomarkers for HDAC inhibitors. Drug Discov Ther 2013; 7(4): 129-36
77. Shin S, Lee EM, Cha HJ, et al. MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol 2009; 35(6): 1343-52
78. Humphreys KJ, Cobiac L, Le Leu RK, et al. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2013; 52(6): 459-74
79. Lee EM, Shin S, Cha HJ, et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009; 24(1): 45-50
80. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code?. Mol Oncol 2012; 6(6): 637-56
81. Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011; 30(41): 4231-42
82. Matthias P. Too much or too little, how much HDAC activity is good for you?. Blood 2013; 121(11): 1930-1
83. Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010; 10(54): 462-70
84. Lepore I, Dell'Aversana C, Pilyugin M, et al. HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. PLoS ONE 2013; 8(12): e83018
85. Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog 2013. [Epub ahead of print]
86. Sampath D, Liu C, Vasan K, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119(5): 1162-72
87. Zhang Z, Convertini P, Shen M, et al. Valproic acid causes proteasomal degradation of DICER and influences miRNA expression. PLoS ONE 2013; 8(12): e82895
88. Hunsberger JG, Fessler EB, Wang Z, et al. Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia am J Transl Res 2012; 4(3): 316-32
89. Aluru N, Deak KL, Jenny MJ, Hahn ME. Developmental exposure to valproic acid alters the expression of microRNAs involved in neurodevelopment in zebrafish. Neurotoxicol Teratol 2013; 40: 46-58
90. Kitamura T, Connolly K, Ruffino L, et al. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5. erbB2 mice. J Hepatol 2012; 57(1): 84-91
91. Wang S, Huang J, Lyu H, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostatinduced downregulation of erbB2/ erbB3 and apoptosis in breast cancer cells. Cell Death Dis 2013; 4: e556
92. Takai N, Narahara H. Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet Gynecol Int 2010; 2010: 923824.